1. Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review
- Author
-
Chiara Miano, Paola Di Caterino, Matteo Megna, Elisa Camela, Gabriella Fabbrocini, Gaia De Fata Salvatores, Maurizio Lo Presti, Camela, Elisa, Miano, Chiara, Di Caterino, Paola, Lo Presti, Maurizio, De Fata Salvatores, Gaia, Fabbrocini, Gabriella., and Megna, Matteo
- Subjects
medicine.medical_specialty ,Follicular papules ,Inflammatory dermatosis ,business.industry ,Erythroderma ,Dermatology ,General Medicine ,medicine.disease ,Acitretin ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pityriasis Rubra Pilaris ,Ustekinumab ,medicine ,Humans ,Ultraviolet Therapy ,Pityriasis rubra pilaris ,Dermatologic Agents ,business ,medicine.drug - Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis characterized by hyperkeratotic follicular papules and erythematous-desquamative plaques that tend to progressively evolve into erythroderma. Treatment is challenging given that international guidelines are not available and large-scale trials do not exist. Traditionally, many topical and systemic drugs had been used as consolidated agents; recently, biologicals are gaining increasing importance, promisingly dominating the therapeutic scenario ahead. Herein, we present a case series showing the "past" and the "future" therapeutic approaches to erythrodermic PRP, one case treated with acitretin and nb-UVB phototherapy combination, while the other with ustekinumab, performing also a throughout literature review.
- Published
- 2020
- Full Text
- View/download PDF